See more news releases in: Human Resource & Workforce Management, Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Dividends, Earnings
Psychemedics Corporation Announces 2009 Year End Profits
Declares Quarterly Dividend
ACTON, Mass., Feb. 23 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2009. The Company also announced a quarterly dividend of $0.12 per share payable to shareholders of record as of March 5, 2010 to be paid on March 19, 2010. This will be the Company's 54th consecutive quarterly dividend.
The Company's revenue for the year ended December 31, 2009 was $16,954,994, a decrease of 26% as compared to $22,948,604 for 2008. Net income for the year ended December 31, 2009 was $1,527,295 or $0.29 per share, a decrease of 49% from 2008 during which the Company earned $2,968,789 or $0.57 per share. Revenue for the fourth quarter was $4,271,340, a decrease of 11% as compared to $4,824,016 in the fourth quarter of 2008. Net income was $546,083 or $0.10 per share, up 216% from $172,728 or $0.03 per share for the same period of 2008.
Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "Stating the obvious: this was a very tough year for everyone. And so for us as well. On the bright side, we continued to add new clients as more and more companies see our patented hair testing method as a significant cost savings tool. However, the facts are that in 2009 most companies were laying off and not hiring. Therefore, new business was unable to match the significant fall off in hiring across our entire client base."
Kubacki continued: "Nonetheless, again on the bright side, we remained profitable for the year 2009 – and not just marginally profitable – and we continued our unbroken string of profitability since 1993. We were able to achieve this level of profitability because we took significant cost reduction/control actions early, and did them logically and methodically. These included reductions in force, changes in certain benefits such as elimination of bonuses, stock grants, and 401K match for 2009. We also implemented a reduction in base salaries for all personnel in 2009. We were determined to remain profitable."
Kubacki concluded, "Once again, we demonstrated that Psychemedics is able to successfully weather any downturn. The Company's balance sheet remains strong with approximately $5.8 million in cash and short-term investments and no long-term debt. Our directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow. Therefore, we are pleased to declare our fifty-fourth consecutive quarterly dividend."
Psychemedics is the world's largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.
The Psychemedics web site is www.drugtestwithhair.com
Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.
Psychemedics Corporation
Statements of Income
Unaudited
Three Months Ended Twelve Months Ended
December 31, December 31,
2009 2008 2009 2008
--------- --------- --------- ----------
Revenues $4,271,340 $4,824,016 $16,954,994 $22,948,604
Cost of revenues 1,749,276 2,224,289 7,345,016 9,598,515
--------- --------- --------- ----------
Gross profit 2,522,064 2,599,727 9,609,978 13,350,089
--------- --------- --------- ----------
General & administrative 812,395 1,257,268 3,596,774 4,520,074
Marketing & selling 635,939 933,699 2,961,477 3,648,584
Research & development 113,470 112,092 467,435 474,622
--------- --------- --------- ----------
Total operating expenses 1,561,804 2,303,059 7,025,686 8,643,280
--------- --------- --------- ----------
Operating income 960,260 296,668 2,584,292 4,706,809
Interest income 11,154 58,073 45,320 308,034
--------- --------- --------- ----------
Net income before provision
for income taxes 971,414 354,741 2,629,612 5,014,843
Provision for income taxes 425,331 182,013 1,102,317 2,046,054
--------- --------- --------- ----------
Net income $546,083 $172,728 $1,527,295 $2,968,789
========= ========= ========= =========
Basic net income per share $0.11 $0.03 $0.29 $0.57
========= ========= ========= =========
Diluted net income per share $0.10 $0.03 $0.29 $0.57
========= ========= ========= =========
Dividends declared per share $0.12 $0.17 $0.53 $0.66
========= ========= ========= =========
Special dividends declared
per share $0.00 $0.50 $0.00 $0.50
========= ========= ========= =========
Weighted average common
shares outstanding, basic 5,197,232 5,206,158 5,193,329 5,219,141
========= ========= ========= =========
Weighted average common
shares outstanding, diluted 5,204,611 5,215,743 5,204,767 5,245,713
========= ========= ========= =========
Psychemedics Corporation
Consolidated Balance Sheets
December 31, December 31,
2009 2008
---------- ----------
ASSETS
Current Assets:
Cash and cash equivalents $4,840,367 $6,630,119
Short-term investments 1,006,436 --
Accounts receivable, net of allowance for
doubtful accounts of $134,282 in 2009 and
$246,462 in 2008 3,016,084 3,398,455
Prepaid expenses and other current assets 663,433 1,105,886
Deferred tax assets 253,221 449,398
---------- ----------
Total Current Assets 9,779,541 11,583,858
---------- ----------
Fixed Assets:
Equipment & leasehold improvements 10,912,906 10,877,479
Less accumulated depreciation (10,381,599) (10,047,755)
---------- ----------
Net Fixed Assets 531,307 829,724
---------- ----------
Deferred tax assets, long term 204,764 139,021
Other assets 86,814 75,183
---------- ----------
Total Assets $10,602,426 $12,627,786
========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY
Liabilities:
Current Liabilities:
Accounts payable $180,784 $644,894
Accrued expenses 1,090,898 1,268,924
Deferred revenue 36,360 154,080
---------- ----------
Total Current Liabilities 1,308,042 2,067,898
---------- ----------
Commitments and Contingencies
Shareholders' Equity:
Preferred-stock, $0.005 par value, 872,521
shares authorized, no shares issued or
outstanding -- --
Common stock, $0.005 par value; 50,000,000
shares authorized 5,861,872 shares issued in
2009 and 5,843,068 shares issued in 2008 29,309 29,216
Paid-in capital 27,419,359 27,118,743
Accumulated deficit (8,100,920) (6,614,114)
Less - Treasury stock, at cost, 664,523
shares in 2009 and 647,304 shares in 2008 (10,053,364) (9,973,957)
---------- ----------
Total Shareholders' Equity 9,294,384 10,559,888
---------- ----------
Total Liabilities and Shareholders' Equity $10,602,426 $12,627,786
========== ==========
Raymond Ruddy | |
Vice President and Controller | |
(978) 206-8220 | |
SOURCE Psychemedics Corporation
Back to top
RELATED LINKS
http://www.drugtestwithhair.com
